Medicare to cover Novo Nordisk's weight-loss drug for heart patients

Medicare will cover Novo Nordisk's weight-loss drug Wegovy for heart patients, if prescribed to reduce their risk of heart attacks and strokes, Reuters reports. The U.S. Centers for Medicare and Medicaid Services said that obesity drugs, currently not covered by Medicare, would be paid for if they receive U.S. approval for a secondary use that Medicare does cover. The coverage of Wegovy will also open the drug up to government price negotiations under President Joe Biden's Inflation Reduction Act.